• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

14.27 +1.17 (+8.93%)
Delayed Quote Updated: 1:39 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,930,481
Open 13.08
Bid (Size) 14.26 (600)
Ask (Size) 14.28 (300)
Prev. Close 13.10
Today's Range 13.06 - 14.48
52wk Range 12.79 - 25.59
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Syndax (SNDX) Q3 2026 Earnings Call Transcript ↗
November 02, 2026
Revenue surged 82% year-over-year as Revuforj and Niktimvo drive commercial momentum. 
Via The Motley Fool
Topics Earnings
News headline image
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call ↗
November 02, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) reported third-quarter 2026 total revenue of $83.3 million, an 82% increase from the prior-year period, as sales of its Revuforj leukemia treatment and... 
Via MarketBeat
Topics Earnings

Performance

52-Week Range 44.2% below 52-week high
14.27
12.7952W Low 25.5952W High
1 Week 2.6% below 1-week high
12.901W Low 14.651W High

Syndax Pharmaceuticals, Inc. - Common Stock (SNDX) traded between $12.79 and $25.59 over the past 52 weeks and last traded at $14.27, 44.2% below its 52-week high. Over the past week it ranged between $12.90 and $14.65.

Past 12 Months
+4.2%
-20.0%
-25.8%
-28.5%
-33.0%
+3.7%
1W +$0.58
1M -$3.56
3M -$4.97
6M -$5.69
YTD -$7.03
1Y +$0.51

SNDX was +3.7% over the past year, -28.5% over six months, -33.0% year to date, +4.2% in the last week.

12 Months vs Market
SNDX
+3.7%
DIA
+9.4%
SPY
+10.7%
QQQ
+8.8%
IWM
+14.6%

Over the past 12 months SNDX returned +3.7% versus DIA (Dow) +9.4%, SPY (S&P 500) +10.7%, QQQ (Nasdaq 100) +8.8% and IWM (Russell 2000) +14.6%.

Volume & Liquidity 1.48× 3-mo avg
Today 2,930,481 3-mo avg 2.0M
1W
3.2M
1M
2.8M
3M
2.0M
6M
1.9M
YTD
1.7M
1Y
1.8M

SNDX most recently traded 2,930,481 shares against a 3-month average daily volume of 2.0M.

More News

Read More
News headline image
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
November 02, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
November 02, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates ↗
August 04, 2026
Via Chartmill
News headline image
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
October 30, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation in November Investor Conferences
October 30, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
October 26, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
October 17, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
October 15, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
October 12, 2026
Via Chartmill
News headline image
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
October 12, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 02, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation in September Investor Conferences
September 01, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax (SNDX) Q2 2026 Earnings Call Transcript ↗
August 11, 2026
Via The Motley Fool
Topics Earnings
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 05, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings
News headline image
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
August 04, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
July 28, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push ↗
July 14, 2026
Via MarketBeat
News headline image
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 01, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
June 11, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 14.27
When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 11/03/26 01:39 PM ET
What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 991.54M
How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
Syndax Pharmaceuticals, Inc. - Common Stock has 992M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap